Sonitor and Tagnos Announce Strategic Merger, Paving the Way for Enhanced Healthcare Technology Solutions
'This merger is transformative for Sonitor, Tagnos, and healthcare. By combining intelligent workflow software with unparalleled RTLS accuracy, we will deliver unmatched visibility, efficiency, and actionable insights to healthcare facilities.' -Matt Crane
Share
The merger, which received enthusiastic approval from Tagnos's current shareholders, including the venture arm of prominent industry leader Zebra Technologies (www.zebra.com), marks a significant milestone for Sonitor and Tagnos. As a result of the merger, Zebra Ventures and several other institutional investors are now shareholders of Sonitor, Inc., further strengthening Sonitor's position as an innovator in the healthcare technology landscape.
'Zebra Ventures is excited to participate in the future growth of the combined solutions brought to market by this merger. We support Sonitor's vision that indoor locating and the associated software are critical tools to improve the safety and productivity of employees and patients in healthcare and beyond,' said Tony Palcheck, VP, Zebra Ventures.
"This merger represents a transformative moment for Sonitor and Tagnos, and more importantly, for the healthcare industry as a whole," said Matt Crane, CEO of Sonitor. "By integrating Tagnos' intelligent workflow orchestration software with Sonitor's unparalleled RTLS accuracy, we are poised to deliver an end-to-end solution that provides healthcare facilities with unprecedented visibility, efficiency, and actionable insights.'
Sheila Minton, CEO of Tagnos, added, "Our mission at Tagnos has always been to empower healthcare providers with the tools to optimize their operations and improve patient outcomes. Joining forces with Sonitor allows us to accelerate this mission by leveraging their superior RTLS technology. The collective expertise and resources of our combined entity will enable us to deliver truly transformative solutions that address the most pressing challenges in healthcare today."
The combined entity will offer a holistic solution that leverages precise location data to automate and optimize a wide range of healthcare processes, including:
Asset Tracking and Management: Real-time visibility into the location and status of critical equipment, reducing search times and improving utilization.
Patient Flow Optimization: Streamlining patient journeys, reducing wait times, and improving throughput in busy healthcare environments.
Staff Safety & Workflow Efficiency: Enhancing communication and coordination among healthcare staff, leading to improved productivity and reduced clinician burnout.
Infection Control: Automating hand hygiene compliance monitoring and contact tracing for enhanced patient safety.
Environmental Monitoring: Ensuring optimal conditions for sensitive medications and equipment.
With the combined strengths of Sonitor and Tagnos, healthcare organizations will gain a powerful platform to enhance operational efficiency, improve patient satisfaction, and deliver higher quality care. The newly merged company is committed to continued innovation and providing cutting-edge solutions that meet the evolving needs of the global healthcare market.
What's Next: Sonitor and Tagnos will continue without disruption to current customers, and the seamless transition prioritizes the success of existing and new customers alike. Meanwhile, work has already begun to accelerate innovations that promise to further bring together RTLS data, workflow automation, and cross-platform interoperability.
About Sonitor: Sonitor is a leading provider of accurate and reliable Real-Time Location System (RTLS) solutions, enabling healthcare organizations to improve operational efficiency, enhance patient safety, and optimize workflows. SonitorONE™ RTLS technology delivers the most accurate and reliable indoor positioning in the market, providing real-time visibility into the location and status of patients, staff, and assets. Learn more at www.sonitor.com.
About Tagnos: Tagnos, founded by Neeraj Bhavani, is a provider of software solutions that orchestrate asset management, inventory management, and clinical workflows, leveraging artificial intelligence and machine learning to optimize healthcare operations. Tagnos's software platform provides actionable insights that improve patient flow, staff efficiency, and overall hospital performance.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Ketjen Introduces New Breakthrough Catalyst Technology that Effectively Mitigates the Effects of Iron Poisoning in FCC Units
Commercial trial demonstrates SaFeGuard's™ effectiveness in processing opportunity crudes HOUSTON, August 20, 2025--(BUSINESS WIRE)--Ketjen Corporation, a leader in catalyst and specialty chemicals manufacturing has launched SaFeGuard™, a new catalyst technology designed to address iron (Fe) poisoning in FCC units. In a recent 30-day full commercial trial, SaFeGuard™ demonstrated a 77% improvement in accessibility with a 50% inventory replacement enabling an increase in unit activity, improved bottoms cracking, and ability to process heavy iron-rich feedstocks. Further testing and predictive modeling suggest that a full 100% inventory changeout could yield up to a 130% increase in accessibility delivering additional improvement in performance. SaFeGuard™ delivers a step change in the contaminant Fe and calcium (Ca) tolerance window by minimizing the Eutectic formation, thereby keeping catalyst pores open. This enables higher activity levels and furthers bottoms cracking, ultimately uplifting profit margins. "We've developed a powerful, safe and sustainable solution that addresses iron poisoning and will increase profitability for our customers by allowing for lower-cost feeds and more efficient operations," said Ketjen's Chief Commercial Officer Henri Tausch. "This new technology is the culmination of decades of research aimed at developing industry leading iron and calcium tolerant catalysis and illustrates our commitment to developing innovative solutions that support the evolving needs of our customers." "SaFeGuard™ is a great option for refiners who are taking advantage of opportunity crudes and even bio feeds because it is just as effective in combating additional contaminants including nickel, vanadium, calcium, sodium, and silicon," said David Leach, Vice President and General Manager, FCC at Ketjen. "It can be used to process iron-rich feedstocks including heavy, resid, tight oil and renewable feeds, and it's also great for units facing accessibility limitations because it requires less frequent catalyst replacement." Ketjen's next generation SaFeGuard™ technology is currently available for use by refiners around the globe. Contact us to learn more about how you can unlock the full potential of your FCC unit. About Ketjen Ketjen is a provider of advanced catalyst solutions to leading producers in the petrochemical, refining and specialty chemicals industries. From fluidized catalytic cracking to clean fuels solutions to hydro-processing to organometallics and curatives, Ketjen delivers safe and reliable solutions that increase production performance and business value. A wholly owned subsidiary of Albemarle Corporation (NYSE: ALB), Ketjen Corporation is headquartered in Houston, Texas, and serves global customers through operations in 25 markets. For more information, visit View source version on Contacts Media Contact: Jennifer Albert, MediaRelations@ Sign in to access your portfolio
Business Wire
an hour ago
- Business Wire
Ketjen Introduces New Breakthrough Catalyst Technology that Effectively Mitigates the Effects of Iron Poisoning in FCC Units
HOUSTON--(BUSINESS WIRE)--Ketjen Corporation, a leader in catalyst and specialty chemicals manufacturing has launched SaFeGuard™, a new catalyst technology designed to address iron (Fe) poisoning in FCC units. In a recent 30-day full commercial trial, SaFeGuard™ demonstrated a 77% improvement in accessibility with a 50% inventory replacement enabling an increase in unit activity, improved bottoms cracking, and ability to process heavy iron-rich feedstocks. Further testing and predictive modeling suggest that a full 100% inventory changeout could yield up to a 130% increase in accessibility delivering additional improvement in performance. SaFeGuard™ delivers a step change in the contaminant Fe and calcium (Ca) tolerance window by minimizing the Eutectic formation, thereby keeping catalyst pores open. This enables higher activity levels and furthers bottoms cracking, ultimately uplifting profit margins. 'We've developed a powerful, safe and sustainable solution that addresses iron poisoning and will increase profitability for our customers by allowing for lower-cost feeds and more efficient operations,' said Ketjen's Chief Commercial Officer Henri Tausch. 'This new technology is the culmination of decades of research aimed at developing industry leading iron and calcium tolerant catalysis and illustrates our commitment to developing innovative solutions that support the evolving needs of our customers.' 'SaFeGuard™ is a great option for refiners who are taking advantage of opportunity crudes and even bio feeds because it is just as effective in combating additional contaminants including nickel, vanadium, calcium, sodium, and silicon,' said David Leach, Vice President and General Manager, FCC at Ketjen. 'It can be used to process iron-rich feedstocks including heavy, resid, tight oil and renewable feeds, and it's also great for units facing accessibility limitations because it requires less frequent catalyst replacement.' Ketjen's next generation SaFeGuard™ technology is currently available for use by refiners around the globe. Contact us to learn more about how you can unlock the full potential of your FCC unit. About Ketjen Ketjen is a provider of advanced catalyst solutions to leading producers in the petrochemical, refining and specialty chemicals industries. From fluidized catalytic cracking to clean fuels solutions to hydro-processing to organometallics and curatives, Ketjen delivers safe and reliable solutions that increase production performance and business value. A wholly owned subsidiary of Albemarle Corporation (NYSE: ALB), Ketjen Corporation is headquartered in Houston, Texas, and serves global customers through operations in 25 markets. For more information, visit
Associated Press
an hour ago
- Associated Press
AcCELLerated Biologics to Distribute RegenaLase™ Laser System from IPG Medical Corporation Across the United States
Jupiter, FL August 20, 2025 --( )-- AcCELLerated Biologics, LLC, a leading distributor of regenerative medicine technologies, today announced an exclusive agreement with IPG Medical Corporation, a wholly owned subsidiary of IPG Photonics Corporation, to distribute the RegenaLase™ Laser System throughout the United States. This new dual-wavelength laser platform is engineered to treat musculoskeletal soft tissue, including meniscus cartilage and inflammation. The RegenaLase system features two advanced laser modalities: 1550 nm erbium fiber laser for minimally invasive cartilage surgery 980 nm diode laser for non-invasive photobiomodulation therapy This dual functionality enables physicians to provide both in-office pain relief and advanced cartilage treatment — all from a single, compact, and versatile device. 'This partnership with IPG Medical marks a major milestone in regenerative medicine,' said Steve Whyte, CEO and Founder of AcCELLerated Biologics. The 'RegenaLase system merges laser innovation with non-invasive phototherapy, giving physicians powerful tools to reduce pain and restore cartilage—without the complications of traditional surgery. At AcCELLerated Biologics, we remain committed to being first to market with cutting-edge solutions that empower our physicians to deliver exceptional care to their patients.' 'I recently attended a cadaver training course at RMTI in Jupiter, Florida, to learn in detail how the RegenaLase Laser can treat musculoskeletal pathologies. This laser technology is poised to be a game changer,' said Joshua G. Hackel, MD, FAAFP, RMSK, CAQSM, Sports Medicine Specialist at the Andrews Institute for Orthopaedics and Sports Medicine. 'We are looking forward to conducting a prospective study utilizing the RegenaLase Laser System to treat knee osteoarthritis at the Andrews Research and Education Foundation in Gulf Breeze, Florida.' 'I have been fortunate in my career to be involved in some groundbreaking technology and techniques. It has allowed me to help many patients heal from their injuries,' said Michael A. Scarpone, D.O. Scarpone Sports Regenerative, Steubenville, Ohio. 'The RegenaLase laser is one of those technologies that has the potential to help a great many patients with knee osteoarthritis and beyond. I am excited to be participating in this project — past, present, and future.' Clinical studies have demonstrated the effectiveness of RegenaLase when paired with optional biologic adjuncts such as Platelet-Rich Plasma (PRP), adipose tissue, and bone marrow aspirate. Patients have shown significant reductions in pain and measurable improvements in joint function. Designed with ergonomics and flexibility in mind, the system is well-suited for both surgical suites and office-based settings, enabling highly personalized treatment protocols, based on delivering multiple, separated microscopic columns of coagulation to the target tissue. 'We're excited to partner with AcCELLerated Biologics to expand access to the RegenaLase system across the United States,' said Alexander Vybornov, IPG Medical Sr. Director of Partnerships & Commercialization. 'With our expertise in laser innovation and AcCELLerated Biologics' strong clinical support and distribution network, more physicians will be empowered to adopt this advanced laser therapy for pain management and advanced musculoskeletal tissue treatment.' The RegenaLase system is FDA-cleared for coagulation of soft tissue including meniscus cartilage, and temporary relief of pain via tissue heating. About AcCELLerated Biologics, LLC AcCELLerated Biologics is a premier distributor of regenerative medicine devices and biologics, dedicated to equipping physicians with the most advanced technologies to improve patient outcomes. Learn More: Media Contact: Sharon Bruneau [email protected] Contact Information: AcCELLerated Biologics Sharon Bruneau +1 (407) 230-3290 Contact via Email Read the full story here: AcCELLerated Biologics to Distribute RegenaLase™ Laser System from IPG Medical Corporation Across the United States Press Release Distributed by
